Sequence-based diagnostics and precision medicine in bacterial and viral infections: from bench to bedside

Curr Opin Infect Dis. 2023 Aug 1;36(4):228-234. doi: 10.1097/QCO.0000000000000936. Epub 2023 Jun 23.

Abstract

Purpose of review: Nucleic acid sequence-based organism identification plays an important role in the diagnosis and management of transplant and cancer-associated infectious diseases. Here, we provide a high-level overview of advanced sequencing technologies, discuss test performance, and highlight unmet research needs with a focus on immunocompromised hosts.

Recent findings: Next-generation sequencing (NGS) technologies are powerful tools with a growing role in managing immunocompromised patients with suspected infection. Targeted NGS (tNGS) can identify pathogens directly from patient specimens, especially for mixed samples, and has been used to detect resistance mutations in transplant-related viruses (e.g. CMV). Whole-genome sequencing (WGS) is increasingly used for outbreak investigations and infection control. Metagenomic NGS (mNGS) is useful for hypothesis-free testing and can simultaneously assess pathogens and host response to infection.

Summary: NGS testing increases diagnostic yield relative to standard culture and Sanger sequencing but may be limited by high cost, turnaround times, and detection of unexpected organisms or commensals of uncertain significance. Close collaboration with the clinical microbiology laboratory and infectious diseases is recommended when NGS testing is considered. Additional research is required to understand which immunocompromised patients are most likely to benefit from NGS testing, and when testing should ideally be performed.

Publication types

  • Review

MeSH terms

  • Clinical Laboratory Services*
  • Communicable Diseases*
  • High-Throughput Nucleotide Sequencing
  • Humans
  • Precision Medicine
  • Virus Diseases* / diagnosis